Login to Your Account

Chasing RSV leaders, Ark's AK0529 clears hurdle in phase I

By Shannon Ellis
Staff Writer

Thursday, September 24, 2015
SHANGHAI – Ark Biosciences Inc. successfully completed a phase I trial for AK0529, an oral drug designed to treat respiratory syncytial virus.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription